American Vanguard (AVD) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Dec, 2025Executive summary
New CEO Dak Kaye is leading a transformation focused on safety, simplification, and operational improvement, with a streamlined structure and modern ERP system.
Achieved full-year 2024 adjusted EBITDA in line with target range, with significant inventory and debt reduction in Q4.
Incurred $118 million in non-recurring charges in 2024, including asset impairments, SIMPAS exit, transformation costs, and investment write-downs.
Preliminary Q4 2024 net sales were $169 million, slightly down from $172 million in Q4 2023.
Management is prioritizing profitability and long-term growth through business transformation initiatives.
Financial highlights
FY 2024 adjusted revenue was $563 million, down from $579 million in 2023; Q4 2024 revenue was $169 million.
FY 2024 adjusted EBITDA was $42 million, within guidance but down from $53 million in 2023; Q4 2024 adjusted EBITDA was $18 million.
Adjusted EBITDA margin for 2024 was 7.5%, compared to 9.1% in 2023.
Inventory reduced by $47 million in Q4 2024, ending at $178–$180 million.
Total debt decreased to $156 million at year-end, down from $179 million in Q3 and $211 million at mid-year 2024.
Outlook and guidance
2025 revenue target is $565–$585 million; adjusted EBITDA target is $45–$52 million.
CapEx for 2025 is expected to be $10 million, with free cash flow prioritized for debt reduction.
Management anticipates gradual improvement in 2025 and further margin enhancement in 2026 and beyond.
Transformation costs in 2025 are projected at $5 million, significantly lower than 2024.
Continued inventory improvement expected in 2025.
Latest events from American Vanguard
- 2025 margins improved and losses narrowed; 2026 targets higher EBITDA and growth from new products.AVD
Q4 202516 Mar 2026 - Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 20242 Feb 2026 - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 202415 Jan 2026 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing2 Dec 2025 - Adjusted EBITDA up 350%, gross margin 29%, and net loss narrowed on strong U.S. crop sales.AVD
Q3 202517 Nov 2025 - Q1 sales dropped 14% with a net loss, but cost cuts and lower debt support recovery.AVD
Q1 202514 Nov 2025 - Adjusted EBITDA nearly doubled and gross margin hit a five-quarter high as net loss narrowed.AVD
Q2 20257 Aug 2025